StreetInsider.com News Articles

Maxim Group Downgrades Iterum Therapeutics (ITRM) to Hold

Wed, 04 Mar 2026 07:37:57 -0500

Maxim Group analyst Jason McCarthy downgraded Iterum Therapeutics (NASDAQ: ITRM) from Buy to Hold.

For an analyst ratings summary and ratings history on Iterum Therapeutics click here. For more ratings news on Iterum Therapeutics click here.

Shares of Iterum Therapeutics closed at $0.15 yesterday.

Form 8-K Iterum Therapeutics plc For: Mar 03

Tue, 03 Mar 2026 16:46:00 -0500

si-local-file:///var/storage/secattach/20260303/26102839.html

Form 8-K Iterum Therapeutics plc For: Mar 03

Tue, 03 Mar 2026 16:46:00 -0500

si-local-file:///var/storage/secattach/20260303/26102839.html

Form 8-K Iterum Therapeutics plc For: Feb 24

Mon, 02 Mar 2026 17:01:00 -0500

si-local-file:///var/storage/secattach/20260302/26093503.html

Form 8-K Iterum Therapeutics plc For: Feb 24

Mon, 02 Mar 2026 17:01:00 -0500

si-local-file:///var/storage/secattach/20260302/26093503.html

Form 8-K Iterum Therapeutics plc For: Feb 18

Wed, 18 Feb 2026 17:06:00 -0500

si-local-file:///var/storage/secattach/20260218/26023419.html

Form 8-K Iterum Therapeutics plc For: Feb 18

Wed, 18 Feb 2026 17:06:00 -0500

si-local-file:///var/storage/secattach/20260218/26023419.html

Form DEFA14A Iterum Therapeutics plc

Fri, 13 Feb 2026 16:31:00 -0500

si-local-file:///var/storage/secattach/20260213/26000968.html

Form DEFA14A Iterum Therapeutics plc

Fri, 13 Feb 2026 16:31:00 -0500

si-local-file:///var/storage/secattach/20260213/26000968.html

Iterum Therapeutics expands ORLYNVAH coverage, receives new patent

Fri, 13 Feb 2026 08:01:06 -0500

Iterum Therapeutics plc (NASDAQ: ITRM) announced a rebate agreement with one of the top three Medicare Part D Pharmacy Benefit Managers, expanding potential coverage for its antibiotic ORLYNVAH to more than 3.5 million lives beginning as early as this quarter.

The Dublin and Chicago-based company received a U.S. patent numbered 12,544,337 covering a bilayer tablet comprising sulopenem etzadroxil and probenecid. The patent, titled "Combinations of Beta-Lactam Compounds and Probenecid and Uses Thereof," is projected to expire in December 2039 and covers methods of treating diseases including uncomplicated urinary tract infections.

The Food and Drug Administration responded to Iterum's request regarding the use

Iterum Therapeutics expands ORLYNVAH coverage, receives new patent

Fri, 13 Feb 2026 08:01:06 -0500

The Food and Drug Administration responded to Iterum's request regarding the use

Iterum Therapeutics Provides Business Update

Fri, 13 Feb 2026 08:00:00 -0500

--Expanded Market Access and Patent Protection for ORLYNVAH™

--FDA correspondence regarding the use of ORLYNVAH™ as step-down therapy

DUBLIN and CHICAGO, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum” or “we”), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today provided a business update.

Recent Events

Market Access Update:
- Medicare Part D Milestone: We are pleased to announce another signed rebate agreement with one of

Iterum Therapeutics Provides Business Update

Fri, 13 Feb 2026 08:00:00 -0500

--Expanded Market Access and Patent Protection for ORLYNVAH™

--FDA correspondence regarding the use of ORLYNVAH™ as step-down therapy

Recent Events

Market Access Update:
- Medicare Part D Milestone: We are pleased to announce another signed rebate agreement with one of

Form DEFA14A Iterum Therapeutics plc

Mon, 26 Jan 2026 16:30:00 -0500

si-local-file:///var/storage/secattach/20260126/25893735.html

Form DEFA14A Iterum Therapeutics plc

Mon, 26 Jan 2026 16:30:00 -0500

si-local-file:///var/storage/secattach/20260126/25893735.html

Form DEF 14A Iterum Therapeutics plc For: Jan 02

Fri, 02 Jan 2026 17:15:00 -0500

si-local-file:///var/storage/secattach/20260102/25799256.html

Form DEF 14A Iterum Therapeutics plc For: Jan 02

Fri, 02 Jan 2026 17:15:00 -0500

si-local-file:///var/storage/secattach/20260102/25799256.html

Form PRE 14A Iterum Therapeutics plc For: Dec 23

Tue, 23 Dec 2025 17:15:00 -0500

si-local-file:///var/storage/secattach/20251223/25778070.html

Form PRE 14A Iterum Therapeutics plc For: Dec 23

Tue, 23 Dec 2025 17:15:00 -0500

si-local-file:///var/storage/secattach/20251223/25778070.html

Iterum Therapeutics expands ORLYNVAH market access with major PBM deal

Tue, 23 Dec 2025 08:01:32 -0500

Iterum Therapeutics plc (NASDAQ: ITRM) announced it secured a commercial contract with a Group Purchasing Organization representing one of the largest Pharmacy Benefit Managers in the United States, adding coverage for more than 24 million lives starting in early 2026.

The Dublin and Chicago-based antibiotic developer also signed a rebate agreement with one of the top three Medicare Part D Pharmacy Benefit Managers. This agreement positions ORLYNVAH for inclusion on Medicare Advantage Prescription Drug and Medicare Prescription Drug formularies, with coverage of more than 10 million lives expected to begin in the first quarter of 2026.

ORLYNVAH, an oral antibiotic approved by

Iterum Therapeutics Provides Business Update

Tue, 23 Dec 2025 08:00:00 -0500

Expanded Market Access for ORLYNVAHTM

DUBLIN and CHICAGO, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum” or “we”), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today provided a business update.

Recent Events

Market Access Update:
- Payor Reimbursement and Contracting Expands with Major PBM Agreement: ORLYNVAH™’s market access continues to accelerate. We have finalized another commercial contract with a Group Purchasing Organization that collaborates with manufacturers on behalf of

Iterum Therapeutics Provides Business Update

Tue, 23 Dec 2025 08:00:00 -0500

Expanded Market Access for ORLYNVAHTM

Recent Events

Market Access Update:
- Payor Reimbursement and Contracting Expands with Major PBM Agreement: ORLYNVAH™’s market access continues to accelerate. We have finalized another commercial contract with a Group Purchasing Organization that collaborates with manufacturers on behalf of

Iterum Therapeutics secures major PBM contract covering 40 million lives

Wed, 17 Dec 2025 08:01:07 -0500

Iterum Therapeutics plc (NASDAQ: ITRM) announced it has finalized a commercial contract with a Group Purchasing Organization that works with one of the largest Pharmacy Benefit Managers in the United States. The agreement will provide coverage opportunities for more than 40 million lives starting in early 2026.

The Dublin and Chicago-based company plans to launch targeted campaigns focused on prescribers in high-coverage areas beginning in the first quarter of 2026. Additional Commercial and Medicare Part D agreements are currently pending execution, according to the company's statement.

The Japanese Patent Office has issued a Decision to Grant for Japanese Patent Application No. 2022-554381,

Iterum Therapeutics Provides Business Update

Wed, 17 Dec 2025 08:00:00 -0500

DUBLIN and CHICAGO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum” or “we”), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today provided a business update.

Recent Events

Market Access Update:
- Payor Reimbursement and Contracting Expands with Major PBM Agreement: ORLYNVAH™’s market access continues to accelerate. We have finalized a commercial contract with a Group Purchasing Organization that collaborates with manufacturers on behalf of one of the largest

Iterum Therapeutics Provides Business Update

Wed, 17 Dec 2025 08:00:00 -0500

Recent Events

Market Access Update:
- Payor Reimbursement and Contracting Expands with Major PBM Agreement: ORLYNVAH™’s market access continues to accelerate. We have finalized a commercial contract with a Group Purchasing Organization that collaborates with manufacturers on behalf of one of the largest